A small-molecule PI3Kα activator for cardioprotection and neuroregeneration

Abstract

Harnessing the potential beneficial effects of kinase signalling through the generation of direct kinase activators remains an underexplored area of drug development1–5. This also applies to the PI3K signalling pathway, which has been extensively targeted by inhibitors for conditions with PI3K overactivation, such as cancer and immune dysregulation. Here we report the discovery of UCL-TRO-1938 (referred to as 1938 hereon), a small-molecule activator of the PI3Kα isoform, a crucial effector of growth factor signalling. 1938 allosterically activates PI3Kα through a distinct mechanism by enhancing multiple steps of the PI3Kα catalytic cycle and causes both local and global conformational changes in the PI3Kα structure. This compound is selective for PI3Kα over other PI3K isoforms and multiple protein and lipid kinases. It transiently activates PI3K signalling in all rodent and human cells tested, resulting in cellular responses such as proliferation and neurite outgrowth. In rodent models, acute treatment with 1938 provides cardioprotection from ischaemia–reperfusion injury and, after local administration, enhances nerve regeneration following nerve crush. This study identifies a chemical tool to directly probe the PI3Kα signalling pathway and a new approach to modulate PI3K activity, widening the therapeutic potential of targeting these enzymes through short-term activation for tissue protection and regeneration. Our findings illustrate the potential of activating kinases for therapeutic benefit, a currently largely untapped area of drug development. A new specific, small-molecule activator of the PI3Kα isoform (UCL-TRO-1938) identified through high-throughput screening can transiently activate PI3K signalling and biological responses in cells and tissues, with potential therapeutic applications in tissue protection and regeneration.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 89

1. 1.

   Cowan-Jacob SW, Jahnke W, Knapp S. Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. Future medicinal chemistry. 2014;6:541-561.

   Not in our library10.4155/fmc.13.216

2. 2.

   Astl L, Tse A, Verkhivker GM. Interrogating Regulatory Mechanisms in Signaling Proteins by Allosteric Inhibitors and Activators: A Dynamic View Through the Lens of Residue Interaction Networks. Adv Exp Med Biol. 2019;1163:187-223.

   Not in our library10.1007/978-981-13-8719-79

3. 3.

   Simpson GL, Hughes JA, Washio Y, Bertrand SM. Direct small-molecule kinase activation: Novel approaches for a new era of drug discovery. Curr Opin Drug Discov Devel. 2009;12:585-596.

   Not in our library

4. 4.

   Fang Z, Grutter C, Rauh D. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features. ACS Chem Biol. 2013;8:58-70.

   Not in our library10.1021/cb300663j

5. 5.

   Mobitz H, Jahnke W, Cowan-Jacob SW. Expanding the Opportunities for Modulating Kinase Targets with Allosteric Approaches. Curr Top Med Chem. 2017;17:59-70.

   Not in our library10.2174/1568026616666160719165314

6. 6.

   Vanhaesebroeck B, Perry MWD, Brown JR, Andre F, Okkenhaug K. PI3K inhibitors are finally coming of age. Nat Rev Drug Discov. 2021;20:741-769.

   Not in our library10.1038/s41573-021-00209-1

7. 7.

   Fruman DA, et al. The PI3K Pathway in Human Disease. Cell. 2017;170:605-635.

   Not in our library10.1016/j.cell.2017.07.029

8. 8.

   Borges GA, et al. Pharmacological PTEN inhibition: potential clinical applications and effects in tissue regeneration. Regen Med. 2020;15:1329-1344.

   Not in our library10.2217/rme-2019-0065

9. 9.

   Matsuda S, et al. Effective PI3K modulators for improved therapy against malignant tumors and for neuroprotection of brain damage after tumor therapy (Review). International journal of oncology. 2016;49:1785-1790.

   Not in our library10.3892/ijo.2016.3710

10. 10.

    Koh SH, Lo EH. The Role of the PI3K Pathway in the Regeneration of the Damaged Brain by Neural Stem Cells after Cerebral Infarction. J Clin Neurol. 2015;11:297-304.

    Not in our library10.3988/jcn.2015.11.4.297

11. 11.

    Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res. 2004;61:448-460.

    Not in our library10.1016/j.cardiores.2003.09.024

12. 12.

    Catanese L, Tarsia J, Fisher M. Acute Ischemic Stroke Therapy Overview. Circ Res. 2017;120:541-558.

    Not in our library10.1161/circresaha.116.309278

13. 13.

    Bala F, et al. Infarct Growth despite Successful Endovascular Reperfusion in Acute Ischemic Stroke: A Meta-analysis. AJNR Am J Neuroradiol. 2021.

    Not in our library10.3174/ajnr.a7177

14. 14.

    Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol. 2020;17:773-789.

    Not in our library10.1038/s41569-020-0403-y

15. 15.

    Chauhan A, et al. PTEN inhibitor bpV(HOpic) confers protection against ionizing radiation. Scientific reports. 2021;11:1720.

    Not in our library10.1038/s41598-020-80754-8

16. 16.

    Iosifidis T, et al. Aberrant cell migration contributes to defective airway epithelial repair in childhood wheeze. JCI insight. 2020;5.

    Not in our library10.1172/jci.insight.133125

17. 17.

    Arnes M, Romero N, Casas-Tinto S, Acebes A, Ferrus A. PI3K activation prevents Abeta42-induced synapse loss and favors insoluble amyloid deposit formation. Mol Biol Cell. 2020;31:244-260.

    Not in our library10.1091/mbc.e19-05-0303

18. 18.

    Cuesto G, et al. Phosphoinositide-3-kinase activation controls synaptogenesis and spinogenesis in hippocampal neurons. J Neurosci. 2011;31:2721-2733.

    Not in our library10.1523/jneurosci.4477-10.2011

19. 19.

    Asua D, Bougamra G, Calleja-Felipe M, Morales M, Knafo S. Peptides Acting as Cognitive Enhancers. Neuroscience. 2018;370:81-87.

    Not in our library10.1016/j.neuroscience.2017.10.002

20. 20.

    Nieuwenhuis B, et al. PI 3-kinase delta enhances axonal PIP3 to support axon regeneration in the adult CNS. EMBO molecular medicine. 2020;12:e11674.

    Not in our library10.15252/emmm.201911674

21. 21.

    Prakoso D, et al. Gene therapy targeting cardiac phosphoinositide 3-kinase (p110alpha) attenuates cardiac remodeling in type 2 diabetes. Am J Physiol Heart Circ Physiol. 2020;318:H840-H852.

    Not in our library10.1152/ajpheart.00632.2019

22. 22.

    Chen S, et al. Neuroprotective Role of the PI3 Kinase/Akt Signaling Pathway in Zebrafish. Front Endocrinol (Lausanne). 2017;8:21.

    Not in our library10.3389/fendo.2017.00021

23. 23.

    Ohtake Y, Hayat U, Li S. PTEN inhibition and axon regeneration and neural repair. Neural Regen Res. 2015;10:1363-1368.

    Not in our library10.4103/1673-5374.165496

24. 24.

    Derossi D, Williams EJ, Green PJ, Dunican DJ, Doherty P. Stimulation of mitogenesis by a cell-permeable PI 3-kinase binding peptide. Biochem Biophys Res Commun. 1998;251:148-152.

    Not in our library10.1006/bbrc.1998.9444

25. 25.

    Jo H, et al. Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death. Proc Natl Acad Sci U S A. 2012;109:10581-10586.

    Not in our library10.1073/pnas.1202810109

26. 26.

    Zheng K, et al. Activation of Akt by SC79 protects myocardiocytes from oxygen and glucose deprivation (OGD)/re-oxygenation. Oncotarget. 2017;8:14978-14987.

    Not in our library10.18632/oncotarget.14785

27. 27.

    Spinelli L, Lindsay YE, Leslie NR. PTEN inhibitors: an evaluation of current compounds. Advances in biological regulation. 2015;57:102-111.

    Not in our library10.1016/j.jbior.2014.09.012

28. 28.

    Furet P, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013;23:3741-3748.

    Not in our library10.1016/j.bmcl.2013.05.007

29. 29.

    Burke JE, Perisic O, Masson GR, Vadas O, Williams RL. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110alpha (PIK3CA). Proc Natl Acad Sci U S A. 2012;109:15259-15264.

    Not in our library10.1073/pnas.1205508109

30. 30.

    Chen P, et al. Engineering of an isolated p110alpha subunit of PI3Kalpha permits crystallization and provides a platform for structure-based drug design. Protein Sci. 2014;23:1332-1340.

    Not in our library10.1002/pro.2517

31. 31.

    Maheshwari S, et al. Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase alpha that are critical for catalysis and substrate recognition. J Biol Chem. 2017;292:13541-13550.

    Not in our library10.1074/jbc.m116.772426

32. 32.

    Pirola L, et al. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha). Functions of lipid kinase-deficient PI3Kalpha in signaling. J Biol Chem. 2001;276:21544-21554.

    Not in our library10.1074/jbc.m011330200

33. 33.

    Yang H, et al. Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. Nature. 2017;552:368-373.

    Not in our library10.1038/nature25023

34. 34.
    COSMIC: the Catalogue Of Somatic Mutations In Cancer · 2018

    No notice
35. 35.

    Clark J, et al. Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry. Nat Methods. 2011;8:267-272.

    Not in our library10.1038/nmeth.1564

36. 36.

    Foukas LC, et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature. 2006;441:366-370.

    Not in our library10.1038/nature04694

37. 37.

    Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006;125:733-747.

    Not in our library10.1016/j.cell.2006.03.035

38. 38.

    Tsolakos N, et al. Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors. Proc Natl Acad Sci U S A. 2018;115:12176-12181.

    Not in our library10.1073/pnas.1803446115

39. 39.
    PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K · 2017

    No notice
40. 40.

    Gerber DE, et al. Stromal platelet-derived growth factor receptor alpha (PDGFRalpha) provides a therapeutic target independent of tumor cell PDGFRalpha expression in lung cancer xenografts. Mol Cancer Ther. 2012;11:2473-2482.

    Not in our library10.1158/1535-7163.mct-12-0431

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.